Startups
2014
PEPTOMYC SLNew generation of cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment
Address
Carrer de Natzaret 115, 08035 Barcelona, Spain
Finance Data
CERCA ownership
Barcelona, Spain
2006
Vall d’Hebron Institut d’Oncologia (VHIO)
CERCA Center Contact
MD
Mario De la Cuesta Rivero
Vall d’Hebron Institut d’Oncologia (VHIO)Other Catalan Public owners
Logo
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
The company was founded in December 2014 and it is based on Dr. Soucek’s scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years.
Product description
Peptomyc has adopted a different strategy based on the inhibition of the oncoprotein Myc, which is found deregulated in the majority of human cancers. Myc holds a non-redundant function in cancer around which tumors cannot evolve, hence targeting Myc is the most promising therapeutic opportunity to date. Although Myc plays a central role in cancer there is currently no Myc inhibitor in the market.
the Omomyc peptide itself displays excellent cell penetrating properties and can efficiently enter cells and exert a strong anti-Myc activity that results in arrest/death of cancer cells. Peptomyc now is developing the Omomyc mini-protein – and improved variants – into clinically viable therapeutics for the treatment of cancer patients.
the Omomyc peptide itself displays excellent cell penetrating properties and can efficiently enter cells and exert a strong anti-Myc activity that results in arrest/death of cancer cells. Peptomyc now is developing the Omomyc mini-protein – and improved variants – into clinically viable therapeutics for the treatment of cancer patients.